Lenvatinib has had promising results from a phase I clinical trial in 2006 and is being tested in several phase II trials as of October 2011[update], for example against hepatocellular carcinoma. After a phase II trial testing the treatment of thyroid cancer has been completed with modestly encouraging results, the manufacturer launched a phase III trial in March 2011.
^Gild, M. L.; Bullock, M.; Robinson, B. G.; Clifton-Bligh, R. (2011). "Multikinase inhibitors: A new option for the treatment of thyroid cancer". Nature Reviews Endocrinology7 (10): 617–624. doi:10.1038/nrendo.2011.141. PMID21862995.edit